Wockhardt Limited promoters have confirmed that no new encumbrances were created on their shares during the financial year ended March 31, 2026. This declaration, submitted by Dr. Habil Khorakiwala on behalf of all promoters and Persons Acting in Concert (PAC), ensures that the shareholding remains free from additional charges other than those previously disclosed. The disclosure is critical for shareholders as it indicates the stability of the promoter's pledged holdings, directly impacting the company's governance profile.

The filing was made in compliance with Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares & Takeover) Regulations, 2011. Dr. Habil Khorakiwala, a promoter of wockhardt , affirmed that neither the promoters nor members of the promoter group, along with PACs, have created any direct or indirect encumbrance during the specified period.

Promoter Shareholding Details

The declaration included an annexure detailing the specific shareholding of the promoter group. The collective holding of the promoters and members of the promoter group stands at 49.09% of the total share capital. The majority of these shares are held through trustee companies on behalf of various partnership firms and discretionary trusts.

Breakdown of Holdings

The document also noted that certain entities such as Ms. Zahabiya Khorakiwala, Dartmour Holdings Private Limited, Palanpur Holdings and Investments Private Limited, and Khorakiwala Holdings and Investments Private Limited form part of the promoter group but hold nil shares. The shares listed under the Partnership Firm and Trust categories are held by the respective companies in their capacity as trustees.

Wockhardt Limited has reported a revenue of INR3,373 crores and an EBITDA of INR630 crores for the current financial year, representing an EBITDA growth of 51%. The company’s profitability before tax stood at INR238 crores, while it holds a cash equivalent of INR662 crores and a net debt-to-equity ratio of 0.1. These results were shared during an investor conference held on June 04, 2026.

The company’s financial performance reflects a strategic shift towards profitability over the last three years, with the EBITDA margin rising from 5.4% to 18.6%. Wockhardt exited its loss-making US generic business to focus on higher-margin segments. The specialty business, comprising biosimilars and novel antibiotics, now contributes 23% of the total business. The biosimilar and biotech business grew by 27%, driven by production improvements in human insulin and Glargine.

Financial and Operational Highlights

Regionally, the emerging market business, which accounts for 28% of turnover, grew by 35%, supported by strategic partnerships in Brazil, Thailand, Algeria, and Malaysia. The UK business, comprising 39% of total operations, grew by 13% with a focus on specialty injectables. The India business is driven by an innovative portfolio including Emrok, Miqnaf, and regenerative medicine.

Strategic Growth Drivers

Wockhardt is entering a new phase of growth centered on its novel antibiotic platform. The company received US FDA approval for Zaynich, making it the first Indian company to have an Indian research product approved by the US FDA. Zaynich is a beta-lactamase enhancer antibiotic designed to treat carbapenem-resistant gram-negative infections. The management plans to launch Zaynich globally, starting with the US and India in the current year, followed by Europe and emerging markets in subsequent years.

The company has onboarded a specialized leadership team for the US market, including experts in commercialization, medical affairs, and market access. The US commercialization strategy will be asset-light, partnering with a commercialization partner for logistics and operational aspects while retaining strategy and execution in-house. The company expects to breakeven on the bottom line for the Zaynich business within 12 to 18 months.

Future Outlook

Looking ahead, Wockhardt aims to accelerate its biotech business, focusing on diabetes biosimilars. The company has registered in 30 emerging markets and has five products in the pipeline, including Aspart, RN 30/70, Degludec, Degludec Aspart, and Semaglutide. The management projects a normal capital expenditure of INR200 crores to INR300 crores over the next three years, primarily for increasing biological capacity.

The company estimates the global peak sales potential for Zaynich to be between $1.5 billion and $2 billion annually. In the US, the daily cost for newer antibiotics is estimated between $1,200 and $1,500, with India prices expected to be discounted by 75% to 80% relative to US pricing. Wockhardt intends to maintain its focus on antibiotic research for the next decade.